Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Distinct properties of c-myc transcriptional elongation are revealed in Xenopus oocytes and mammalian cells and by template titration, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), and promoter mutagenesis.
Meulia T
,
Krumm A
,
Groudine M
.
???displayArticle.abstract???
A block to c-myc transcription elongation has been observed in Xenopus oocytes and mammalian cells. Here, we show that the distribution of RNA polymerase II transcription complexes in the c-myc promoter proximal region in Xenopus oocytes is different from that observed previously in mammalian cells. Thus, there are major differences in the c-myc elongation block observed in the two systems. In addition, as first reported for a Xenopus tubulin gene (K. M. Middleton and G. T. Morgan, Mol. Cell. Biol. 10:727-735, 1990). c-myc template titration experiments reveal the existence of two classes of RNA polymerase II transcription complexes in oocytes: one (at low template concentration) that is capable of reading through downstream sites of premature termination, and another (high template concentration) that does not. We show that these classes of polymerases are distinct from those previously identified by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), which distinguishes transcription complexes on the basis of transcribed distance, rather than on the basis of differential elongation through sites of premature termination. We also show that mutations that affect the efficiency of initiation of transcription from the c-mycP2 promoter can influence premature termination by at least two mechanisms: TATA box mutations function by the titration effect (decrease in transcription initiation results in a relative decrease in premature termination), while an upstream activator (E2F) site functions by contributing to the assembly of polymerase complexes competent to traverse the downstream sites of premature termination.
ar-Rushdi,
Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma.
1983, Pubmed
ar-Rushdi,
Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma.
1983,
Pubmed
Ashfield,
Transcriptional termination between the closely linked human complement genes C2 and factor B: common termination factor for C2 and c-myc?
1991,
Pubmed
Asselin,
Molecular requirements for transcriptional initiation of the murine c-myc gene.
1989,
Pubmed
Bengal,
Role of the mammalian transcription factors IIF, IIS, and IIX during elongation by RNA polymerase II.
1991,
Pubmed
Bentley,
Sequence requirements for premature termination of transcription in the human c-myc gene.
1988,
Pubmed
,
Xenbase
Bentley,
A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells.
,
Pubmed
Bentley,
Accurate, TATA box-dependent polymerase III transcription from promoters of the c-myc gene in injected Xenopus oocytes.
1989,
Pubmed
,
Xenbase
Bossone,
MAZ, a zinc finger protein, binds to c-MYC and C2 gene sequences regulating transcriptional initiation and termination.
1992,
Pubmed
Buckler,
Transcriptional control of c-myc gene expression during stimulation of murine B lymphocytes.
1990,
Pubmed
Burton,
RAP30/74: a general initiation factor that binds to RNA polymerase II.
1988,
Pubmed
Chafin,
Identification and purification of a yeast protein that affects elongation by RNA polymerase II.
1991,
Pubmed
Chang,
Effects of IL-3 on promoter usage, attenuation and antisense transcription of the c-myc oncogene in the IL-3-dependent Ba/F3 early pre-B cell line.
1991,
Pubmed
Chodosh,
5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription elongation by RNA polymerase II in vitro.
1989,
Pubmed
Chung,
The c-myc gene encodes superimposed RNA polymerase II and III promoters.
1987,
Pubmed
,
Xenbase
Eick,
Transcription of c-myc in human mononuclear cells is regulated by an elongation block.
1987,
Pubmed
Eick,
Transcriptional arrest within the first exon is a fast control mechanism in c-myc gene expression.
1986,
Pubmed
Flores,
Factors involved in specific transcription by mammalian RNA polymerase II. Factors IIE and IIF independently interact with RNA polymerase II.
1989,
Pubmed
Giardina,
Promoter melting and TFIID complexes on Drosophila genes in vivo.
1992,
Pubmed
Hiebert,
E1A-dependent trans-activation of the human MYC promoter is mediated by the E2F factor.
1989,
Pubmed
Innis,
A heat-labile factor promotes premature 3' end formation in exon 1 of the murine adenosine deaminase gene in a cell-free transcription system.
1991,
Pubmed
Izban,
The RNA polymerase II ternary complex cleaves the nascent transcript in a 3'----5' direction in the presence of elongation factor SII.
1992,
Pubmed
Kato,
HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors.
1992,
Pubmed
Kephart,
Stability of Drosophila RNA polymerase II elongation complexes in vitro.
1992,
Pubmed
Kerppola,
Intrinsic sites of transcription termination and pausing in the c-myc gene.
1988,
Pubmed
,
Xenbase
Krauskopf,
The block to transcription elongation at the minute virus of mice attenuator is regulated by cellular elongation factors.
1991,
Pubmed
Krumm,
The block to transcriptional elongation within the human c-myc gene is determined in the promoter-proximal region.
1992,
Pubmed
Lee,
DNA sequence requirements for generating paused polymerase at the start of hsp70.
1992,
Pubmed
Lindsten,
Multiple mechanisms regulate c-myc gene expression during normal T cell activation.
1988,
Pubmed
London,
Analysis of premature termination in c-myc during transcription by RNA polymerase II in a HeLa nuclear extract.
1991,
Pubmed
Lüscher,
New light on Myc and Myb. Part I. Myc.
1990,
Pubmed
Marciniak,
HIV-1 Tat protein promotes formation of more-processive elongation complexes.
1991,
Pubmed
Marshall,
Control of formation of two distinct classes of RNA polymerase II elongation complexes.
1992,
Pubmed
Mechti,
Transcriptional and post-transcriptional regulation of c-myc expression during the differentiation of murine erythroleukemia Friend cells.
1986,
Pubmed
Meulia,
Sequences in the human c-myc P2 promoter affect the elongation and premature termination of transcripts initiated from the upstream P1 promoter.
1992,
Pubmed
,
Xenbase
Middleton,
Premature termination of transcription can be induced on an injected alpha-tubulin gene in Xenopus oocytes.
1990,
Pubmed
,
Xenbase
Miller,
A cis-acting element in the promoter region of the murine c-myc gene is necessary for transcriptional block.
1989,
Pubmed
Mirkovitch,
Mapping of RNA polymerase on mammalian genes in cells and nuclei.
1992,
Pubmed
Mukherjee,
5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription of the beta-hemoglobin gene in vivo at initiation.
1987,
Pubmed
Nepveu,
Intragenic pausing and anti-sense transcription within the murine c-myc locus.
1986,
Pubmed
O'Brien,
RNA polymerase II pauses at the 5' end of the transcriptionally induced Drosophila hsp70 gene.
1991,
Pubmed
Pyrc,
Isolation of a novel cDNA encoding a zinc-finger protein that binds to two sites within the c-myc promoter.
1992,
Pubmed
Reinberg,
Factors involved in specific transcription by mammalian RNA polymerase II. Transcription factor IIS stimulates elongation of RNA chains.
1987,
Pubmed
Reines,
Transcription elongation factor SII (TFIIS) enables RNA polymerase II to elongate through a block to transcription in a human gene in vitro.
1989,
Pubmed
Reines,
Elongation factor-dependent transcript shortening by template-engaged RNA polymerase II.
1992,
Pubmed
Roberts,
Distinct modes of transcription read through or terminate at the c-myc attenuator.
1992,
Pubmed
,
Xenbase
Rougvie,
The RNA polymerase II molecule at the 5' end of the uninduced hsp70 gene of D. melanogaster is transcriptionally engaged.
1988,
Pubmed
SivaRaman,
Purified elongation factor SII is sufficient to promote read-through by purified RNA polymerase II at specific termination sites in the human histone H3.3 gene.
1990,
Pubmed
Sluder,
Properties of a Drosophila RNA polymerase II elongation factor.
1989,
Pubmed
Spencer,
Transcription elongation in the human c-myc gene is governed by overall transcription initiation levels in Xenopus oocytes.
1993,
Pubmed
,
Xenbase
Spencer,
Control of c-myc regulation in normal and neoplastic cells.
1991,
Pubmed
Spencer,
Transcription elongation and eukaryotic gene regulation.
1990,
Pubmed
Spencer,
The block to transcription elongation is promoter dependent in normal and Burkitt's lymphoma c-myc alleles.
1990,
Pubmed
,
Xenbase
Strobl,
Hold back of RNA polymerase II at the transcription start site mediates down-regulation of c-myc in vivo.
1992,
Pubmed
Thalmeier,
Nuclear factor E2F mediates basic transcription and trans-activation by E1a of the human MYC promoter.
1989,
Pubmed
Wright,
Premature termination of transcription from the P1 promoter of the mouse c-myc gene.
1991,
Pubmed
,
Xenbase
Wright,
DNA sequences that mediate attenuation of transcription from the mouse protooncogene myc.
1989,
Pubmed
Yanofsky,
Transcription attenuation.
1988,
Pubmed
